跳至主要内容
临床试验/NCT01035346
NCT01035346终止3 期

Evaluation Of The Antipyretic Efficacy Of Ibuprofen Sodium Tablets In Subjects With An Uncomplicated Acute Infection

Pfizer1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2010年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
终止
发起方
Pfizer
入组人数
16
试验地点
1
主要终点
Time-weighted Sum of The Temperature Differences From Baseline Through Hour 6 (STEMPD 0-6)

研究概览

简要总结

This single-dose trial will evaluate the efficacy of a novel ibuprofen formulation compared to placebo in patients with a fever due to an uncomplicated acute infection.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
12 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects diagnosed with a fever secondary to an uncomplicated acute viral or bacterial infection.
  • Oral temperature measurement from 100 to 104 degrees Fahrenheit.
  • Onset of fever 3 days or less.
  • Otherwise good health.

排除标准

  • Fever secondary to a chronic underlying medical condition or serious infection.
  • Currently taking antibiotics or antivirals.
  • Currently taking any medication which may interfere with the assessment of fever.
  • Pregnancy or breast-feeding.
  • Any serious medical or psychiatric disorder.

研究组 & 干预措施

A

Experimental

干预措施: Ibuprofen (Drug)

B

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Time-weighted Sum of The Temperature Differences From Baseline Through Hour 6 (STEMPD 0-6)

时间窗: 0 to 6 hours

STEMPD 0-6 was defined as time-weighted sum of temperature differences over 6 hours, weighted by the time elapsed between each 2 consecutive time points. Temperature difference was defined as baseline temperature minus post-baseline temperature at each time point, where positive value indicated improvement in body temperature.

次要结局

  • Time-weighted Sum of The Temperature Differences From Baseline Through Hour 4 and Hour 8 (STEMPD 0-4 and STEMPD 0-8)(0 to 4, 0 to 8 hours)
  • Change From Baseline in Temperature at Hours 0.25, 0.5, 1, 2, 4, 6 and 8(Baseline, 0.25, 0.5, 1, 2, 4, 6, 8 hours)
  • Time to Treatment Failure(0 to 8 hours)
  • Cumulative Percentage of Participants With Treatment Failure(0.25, 0.5, 1, 2, 4, 6, 8 hours)
  • Global Assessment of Study Medication as an Antipyretic(8 hours)
  • Rating of Study Medication Relative to Usual Medication(8 hours)

研究者

发起方
Pfizer
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Study Evaluating The Efficacy Of A Novel Ibuprofen... | 临床试验